ERBB2 and neoplasm: The rest of HLA-A2, HER-2/neu+ patients (n=12; 75%) were nonresponders, demonstrating low frequencies of peptide-specific CTL (range of PF=0–11.7; mean PF=7.1, P<0.01 compared to mean PF of the four responders), which were almost comparable with those (mean PF) observed in the group of HLA-A2 patients with HER-2/neu− tumours (range of PF=0–11.8; mean PF=5.5) (Figure 1) and of HLA-A2 healthy volunteers (in both cases P: nonsignificant (NS)).